Universal Time: 16:42  |  Local Time: 16:42 (0h GMT)
Select your timezone:

Kidney

-

Room: E-Poster Hall

P-11.43 Urinary beta-2-microglobulin as a biomarker for chronic allograft injury and rapid renal function decline in kidney transplant recipients

Hee Jung Jeon, Korea

Department of Internal Medicine
Hallym University College of Medicine, Kangdong Sacred Heart Hospital

Abstract

Urinary beta-2-microglobulin as a biomarker for chronic allograft injury and rapid renal function decline in kidney transplant recipients

Hee Jung Jeon1, Dong Ho Shin1, Jieun Oh1, Ji Young Park2, Kyungjai Ko3, Joo Seop Kim3, Samuel Lee3.

1Department of Internal Medicine, Hallym University College of Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea; 2Department of Laboratory Medicine, Hallym University College of Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea; 3Department of Surgery, Hallym University College of Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea

Introduction: Chronic allograft injury (CAI) is common after kidney transplantation and the leading cause of allograft loss in kidney transplant recipients (KTRs). The aim of this study was to investigate urinary biomarkers associated with CAI and rapid renal function decline in KTRs.
Materials and Methods: Thirty KTRs whose estimated GFR were less than 60 mL/min/1.73m2 (CAI group) and 20 KTRs with normal allograft function (control group) were included in this study. To identify potential urinary biomarkers, we performed SDS-PAGE followed by liquid chromatography-mass spectrometry (LC-MS/MS). Several urinary proteins including beta-2-microglobulin (B2MG) were validated by ELISA. Rapid renal function decline was defined as estimated GFR decline of >3 mL/min/1.73m2/year or initiation of dialysis for 3 years after baseline sampling.
Results and Discussion: Among protein profiles identified by proteomics, urinary B2MG levels were different between CAI group and control group (9882.0 vs. 1165.7, P<0.001). Urinary B2MG levels measured by ELISA were also higher in CAI group (1686.4±2997.8 vs. 28.1±27.5 ng/mL, P=0.005). Urinary B2MG/creatinine levels had high association with CAI group compared to control group (AUROC 0.770 [0.641-0.899], P<0.001). Among 50 KTRs, 19 patients (38%) were classified as rapid renal function decline group. Urinary B2MG levels were higher in rapid renal function decline group than stable renal function group (2253.5±3615.4 vs. 269.0±631.6 ng/mL, P=0.029). Higher urinary B2MG levels (>2347 ng/mL) were associated with significantly lower graft survival compared to lower urinary B2MG levels (<2347 ng/mL) (log rank test: P=0.006)
Conclusions: These results suggest that urinary B2MG levels might be a potential biomarker for detection of CAI and could be used as predictor for rapid renal function decline in KTRs.

Comments

There are no comments yet...

WebApp Sponsor

© 2021 TTS 2020